Achieve Life Sciences





After Hours:




Please Login or Register

Login|Register FREE

Stock Price
Open: 1.34
Prev. Close: 1.35
Low/Hi: 1.32 - 1.42
52-Week: 1.15 - 6.27
Equity: 97,035
90-Day Avg: 379,055
Todays Stock Vol: 64.8
20-Day (HV): 109.8
52-Week (HV): 124.9
Div. Yield:
Earnings: 15-May (Est.)
P/E Ratio:
Market Cap: 17.2 M
Short Int Pct: 0.0%
Pct Held By Inst.: 2.8%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ACHV

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ACHV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 13.4 B 1.33909E+10 3,455 3455 0.0% 0 25 K 25330
VTI Vanguard Total Stock Market ETF 94.1 B 9.41E+10 3,646 3646 0.0% 0 22 K 21564
VXF Vanguard Extended Market ETF 5.8 B 5.8E+09 3,171 3171 0.0% 0 2 K 1928
WMCR Wilshire Micro-Cap ETF (based on the Wilshire US Micro-Cap Index) 27.9 M 2.79395E+07 801 801 0.01% 0.0001 2 K 1627

Wait, Before You Leave...

Want to Know More About ACHV Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon